Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.

Agnafit Bidco, comprised of Advent International and an affiliate of GIC Pte Ltd, will pay a premium for the rare disease specialist in an effort to capture value from Sobi’s planned growth.  

Arrowhead and Horizon Therapeutics have inked a deal to develop an investigational RNA interference therapy for uncontrolled gout, under which Arrowhead stands to get $40m upfront and up to $660m in milestones.

Sobi is extending its reach in international markets including Russia and China and expects its late-stage R&D pipeline to drive growth.